Histological healing after infliximab induction therapy in children with ulcerative colitis

Table 1 Characteristics of clinical and biochemical parameters before and after induction therapy with infliximab

Parameter	Week 0				Week 8				P value
	mean	Median	Q1	Q3	mean	Median	Q1	Q3
PUCAI score	49.1	50	35	65	16.3	10	10	20	< 0.05
Body weight (kg)	46.5	44	43	56.6	50.4	53.3	42.7	60.5	< 0.05
Body height (cm)	157.3	163	151	168.5	158.2	163.5	152	170	NS
Hemoglobin (g/dL)	9.9	9.8	8.3	11.3	11	11	10	12.2	< 0.05
Hematocrit (%)	35.8	31.5	29.2	35.8	33.9	34.9	30.1	37.2	NS
Platelet count (K/μL)	441.1	427	327.5	558	384	375.5	290	440.5	NS
ESR (mm/h)	33	36	18.5	45	19.8	12.5	7	22.5	< 0.05
CRP (mg/dL)	2.6	2.8	0.4	4.1	0.3	0.2	0	0.4	< 0.05

Q1: Lower quartile; Q3: Upper quartile; NS: Not significant.

Table 2 Characteristics of histological and endoscopic features in ulcerative colitis patients before and after induction therapy with infliximab

Parameter	Week 0	Week 8
Histopathological features
Grade > 3	4/16	1/16
Grade 3	10/16	8/16
Grade 2	2/16	2/16
Grade 1	0/16	2/16
Grade 0	0/16	3/16
Irregular surface	12/16	6/16
Abnormal crypt architecture	9/16	8/16
Reduced number of the crypts	10/16	7/16
Cryptitis	11/16	6/16
Epithelial changes	8/16	6/16
Mucin depletion	6/16	6/16
Increased intraepithelial lymphocytes	3/16	5/16
Baron scale, mean ± SD	2.5 ± 0.6325	1.5 ± 0.9661 (P = 0.0033)
Baron 0	0/16	2/16
Baron 1	1/16	7/16
Baron 2	6/6	4/16
Baron 3	9/16	3/16

Table 3 Correlation between clinical, endoscopic and histological parameters of disease activity

No.	Sex	Week 0			Week 8
		PUCAI	Baron score	Geboesscore	PUCAI	Baronscore	Geboesscore
1	M	70	3	> 3	15	3	3
2	F	75	2	3	25	1	3
3	M	50	2	3	< 10	1	0
4	F	50	3	3	< 10	1	3
5	M	55	2	> 3	< 10	2	3
6	F	25	3	2	< 10	3	3
7	M	40	3	> 3	0	0	2
8	M	10	2	3	65	1	> 3
9	M	45	3	3	0	2	1
10	F	45	3	3	< 10	2	2
11	F	85	3	2	< 10	0	0
12	F	60	3	3	< 10	2	3
13	F	30	2	3	< 10	1	0
14	M	25	2	3	< 10	1	3
15	F	50	3	> 3	35	3	3
16	F	70	1	3	30	1	1

M: Male; F: Female.